BLA 761434 · Otsuka Pharm CO LTD
Voyxact
Sibeprenlimab-Szsi · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Nov 25, 2025: To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 25, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 1 recruiting
FAERS reports
689
114 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 17, 2026.
VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VOYXACT is an A Proliferation Inducing Ligand (APRIL) blocker, indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. ( 1 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. ( 1 )
Mechanism: VOYXACT binds to APRIL with a dissociation constant (K D ) of 0.95 pM, which blocks signaling at the B cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptors. Inhibition of APRIL results in reduced levels of serum galactose-deficient immunoglobulin A1 (Gd-IgA1), which is implicated in the pathogenesis of IgAN.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
- VOYXACT · SIBEPRENLIMAB-SZSI 400MG/2ML(200MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sibeprenlimab" as an intervention, any sponsor and status, largest first.
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingEnrolling by invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05248659 · 600 participants (planned) · Start Apr 5, 2022 · Primary completion Dec 28, 2028
Drug: Sibeprenlimab 400 mg s.c. Q4weeks · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 158 sites in all
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05248646 · 530 participants · Start Mar 15, 2022 · Primary completion May 13, 2026
Drug: Sibeprenlimab 400 mg; Placebo · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 308 sites in all
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06928142 · 83 participants · Start Apr 23, 2025 · Primary completion Mar 13, 2027
Drug: Sibeprenlimab · For: Sjogren Disease
Sites: Riverside, California; Tujunga, California; Brandon, Florida · 63 sites in all
- Phase 2b Open-Label Repeat Kidney Biopsy StudyActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06740526 · 56 participants · Start Dec 5, 2024 · Primary completion Dec 28, 2028
Drug: Sibeprenlimab · For: IgA Nephropathy
Sites: Birmingham, Alabama; Stanford, California; Denver, Colorado · 19 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
Otsuka Beijing Research InstituteOtsuka
NCT07105124 · 24 participants · Start Oct 18, 2022 · Primary completion Feb 15, 2023
Drug: Sibeprenlimab · For: Healthy Subjects (HS)
Sites: Chengdu, China
- Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07770815 · 24 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 29, 2029
Drug: Sibeprenlimab; Standard of care · For: IgA Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07861113 · 20 participants (planned) · Start Dec 15, 2026 · Primary completion Jun 15, 2028
Drug: Sibeprenlimab · For: Primary Membranous Nephropathy; Minimal Change Disease; Focal Segmental Glomerulosclerosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain100
- injection site swelling75
- fatigue68
- injection site erythema51
- injection site pruritus47
- nasopharyngitis43
- cough32
- injection site bruising32
- nausea32
- dizziness29
- headache24
- diarrhoea23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 681 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Perkovic V, Trimarchi H, Tesar V, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.
Chen B, Zhu Y, Yang Y, et al. · Front Med (Lausanne) 2025 · Systematic Review
- Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Tian Z, Li Y · BMC Nephrol 2026 · Systematic Review, Meta-Analysis
- Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
McCafferty K, Barratt J, Suzuki Y, et al. · Clin J Am Soc Nephrol 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis.
Mansour N, Elbarody RMF, Kamel AM · BMC Nephrol 2026 · Network Meta-Analysis, Systematic Review
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.